MAPT and Alzheimer disease: Although increased expression of GSK3 is not the main cause of the disease, augmented GSK3 could serve to enhance the production of Aβ, which in turn also trigger tau hyper-phosphorylation and neuronal degeneration in both FAD and sAD, which is in line with the amyloid cascade hypothesis of AD.